Activation of somatostatin-receptor subtype-2/-5 suppresses the mass, frequency, and irregularity of growth hormone (GH)-releasing peptide-2-stimulated GH secretion in men

Ali Iranmanesh, Cyril Y. Bowers, Johannes D Veldhuis

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Somatostatin antagonizes the stimulatory actions of GHRH and GH-releasing peptides (GHRPs). However, precisely how the inhibitory susceptibilities of the two secretagogues differ is not clear. One interpretative difficulty is that native somatostatin activates six different receptor subtypes. The present study adopts the complementary strategy of enforcing feedback inhibition via the preferential somatostatin receptor subtype 2 and 5 (SSTR-2/-5) agonist, octreotide. We postulated that putative SSTR-2/-5 agonism would unmask secretagogue-selective interactions in the control of GH secretory burst mass, frequency, and/or regularity. To this end, 10 healthy men each underwent eight randomly ordered, separate-day, fast ing morning infusion sessions. Interventions comprised sc administration of octreotide (1 μg/kg), followed by bolus iv injection of saline, GHRH (1 μg/kg), GHRP-2 (1 μg/kg), or both peptides. Compared with placebo, the SSTR-2/-5 agonist reduced fasting GH concentrations from 0.27 ± 0.07 to 0.12 ± 0.02 μg/liter (P = 0.020), GH secretory burst mass from 2.7 ± 0.65 to 0.55 ± 0.11 μg/liter (P = 0.013), and basal GH secretion from 0.24 ± 0.043 to 0.11 ± 0.015 μg/liter·100 min (P = 0.0063). The foregoing outcomes were selective, because octreotide did not alter GH secretory burst frequency (3.1 ± 0.5 vs. 3.3 ± 0.21 events/3 h) or the regularity of the GH release process (approximate entropy, 0.58 ± 0.048 vs. 0.68 ± 0.064). In the GHRP-2-stimulated setting, presumptive SSTR-2/-5 agonism suppressed all three GH secretory burst masses, from 28 ± 3.2 to 18 ± 2.0 (P = 0.045); GH pulse frequency, from 3.3 ± 0.30 to 2.0 ± 0.18 (P = 0.0025); and the irregularity (approximate entropy) of GH release, from 0.648 ± 0.049 to 0.433 ± 0.047 (P < 0.01). In contrast, in the GHRH and combined GHRH/GHRP-2-stimulated contexts, octreotide decreased only GH secretory burst mass (P = 0.047). In summary, the present data indicate that GH secretory burst mass, frequency, and orderliness are subject to interactive control by at least SSTR-2/-5-dependent feedback and GHRP-dependent feedforward signals.

Original languageEnglish (US)
Pages (from-to)4581-4587
Number of pages7
JournalJournal of Clinical Endocrinology and Metabolism
Volume89
Issue number9
DOIs
StatePublished - Sep 2004

Fingerprint

Somatostatin Receptors
Growth Hormone
Chemical activation
Octreotide
Peptides
Entropy
Somatostatin
growth hormone-releasing peptide-2
somatostatin receptor 2
Feedback
Fasting
Placebos
somatostatin receptor 5

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Activation of somatostatin-receptor subtype-2/-5 suppresses the mass, frequency, and irregularity of growth hormone (GH)-releasing peptide-2-stimulated GH secretion in men. / Iranmanesh, Ali; Bowers, Cyril Y.; Veldhuis, Johannes D.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 89, No. 9, 09.2004, p. 4581-4587.

Research output: Contribution to journalArticle

@article{5c655503c4694648a63cd4183372b7c4,
title = "Activation of somatostatin-receptor subtype-2/-5 suppresses the mass, frequency, and irregularity of growth hormone (GH)-releasing peptide-2-stimulated GH secretion in men",
abstract = "Somatostatin antagonizes the stimulatory actions of GHRH and GH-releasing peptides (GHRPs). However, precisely how the inhibitory susceptibilities of the two secretagogues differ is not clear. One interpretative difficulty is that native somatostatin activates six different receptor subtypes. The present study adopts the complementary strategy of enforcing feedback inhibition via the preferential somatostatin receptor subtype 2 and 5 (SSTR-2/-5) agonist, octreotide. We postulated that putative SSTR-2/-5 agonism would unmask secretagogue-selective interactions in the control of GH secretory burst mass, frequency, and/or regularity. To this end, 10 healthy men each underwent eight randomly ordered, separate-day, fast ing morning infusion sessions. Interventions comprised sc administration of octreotide (1 μg/kg), followed by bolus iv injection of saline, GHRH (1 μg/kg), GHRP-2 (1 μg/kg), or both peptides. Compared with placebo, the SSTR-2/-5 agonist reduced fasting GH concentrations from 0.27 ± 0.07 to 0.12 ± 0.02 μg/liter (P = 0.020), GH secretory burst mass from 2.7 ± 0.65 to 0.55 ± 0.11 μg/liter (P = 0.013), and basal GH secretion from 0.24 ± 0.043 to 0.11 ± 0.015 μg/liter·100 min (P = 0.0063). The foregoing outcomes were selective, because octreotide did not alter GH secretory burst frequency (3.1 ± 0.5 vs. 3.3 ± 0.21 events/3 h) or the regularity of the GH release process (approximate entropy, 0.58 ± 0.048 vs. 0.68 ± 0.064). In the GHRP-2-stimulated setting, presumptive SSTR-2/-5 agonism suppressed all three GH secretory burst masses, from 28 ± 3.2 to 18 ± 2.0 (P = 0.045); GH pulse frequency, from 3.3 ± 0.30 to 2.0 ± 0.18 (P = 0.0025); and the irregularity (approximate entropy) of GH release, from 0.648 ± 0.049 to 0.433 ± 0.047 (P < 0.01). In contrast, in the GHRH and combined GHRH/GHRP-2-stimulated contexts, octreotide decreased only GH secretory burst mass (P = 0.047). In summary, the present data indicate that GH secretory burst mass, frequency, and orderliness are subject to interactive control by at least SSTR-2/-5-dependent feedback and GHRP-dependent feedforward signals.",
author = "Ali Iranmanesh and Bowers, {Cyril Y.} and Veldhuis, {Johannes D}",
year = "2004",
month = "9",
doi = "10.1210/jc.2004-0205",
language = "English (US)",
volume = "89",
pages = "4581--4587",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "9",

}

TY - JOUR

T1 - Activation of somatostatin-receptor subtype-2/-5 suppresses the mass, frequency, and irregularity of growth hormone (GH)-releasing peptide-2-stimulated GH secretion in men

AU - Iranmanesh, Ali

AU - Bowers, Cyril Y.

AU - Veldhuis, Johannes D

PY - 2004/9

Y1 - 2004/9

N2 - Somatostatin antagonizes the stimulatory actions of GHRH and GH-releasing peptides (GHRPs). However, precisely how the inhibitory susceptibilities of the two secretagogues differ is not clear. One interpretative difficulty is that native somatostatin activates six different receptor subtypes. The present study adopts the complementary strategy of enforcing feedback inhibition via the preferential somatostatin receptor subtype 2 and 5 (SSTR-2/-5) agonist, octreotide. We postulated that putative SSTR-2/-5 agonism would unmask secretagogue-selective interactions in the control of GH secretory burst mass, frequency, and/or regularity. To this end, 10 healthy men each underwent eight randomly ordered, separate-day, fast ing morning infusion sessions. Interventions comprised sc administration of octreotide (1 μg/kg), followed by bolus iv injection of saline, GHRH (1 μg/kg), GHRP-2 (1 μg/kg), or both peptides. Compared with placebo, the SSTR-2/-5 agonist reduced fasting GH concentrations from 0.27 ± 0.07 to 0.12 ± 0.02 μg/liter (P = 0.020), GH secretory burst mass from 2.7 ± 0.65 to 0.55 ± 0.11 μg/liter (P = 0.013), and basal GH secretion from 0.24 ± 0.043 to 0.11 ± 0.015 μg/liter·100 min (P = 0.0063). The foregoing outcomes were selective, because octreotide did not alter GH secretory burst frequency (3.1 ± 0.5 vs. 3.3 ± 0.21 events/3 h) or the regularity of the GH release process (approximate entropy, 0.58 ± 0.048 vs. 0.68 ± 0.064). In the GHRP-2-stimulated setting, presumptive SSTR-2/-5 agonism suppressed all three GH secretory burst masses, from 28 ± 3.2 to 18 ± 2.0 (P = 0.045); GH pulse frequency, from 3.3 ± 0.30 to 2.0 ± 0.18 (P = 0.0025); and the irregularity (approximate entropy) of GH release, from 0.648 ± 0.049 to 0.433 ± 0.047 (P < 0.01). In contrast, in the GHRH and combined GHRH/GHRP-2-stimulated contexts, octreotide decreased only GH secretory burst mass (P = 0.047). In summary, the present data indicate that GH secretory burst mass, frequency, and orderliness are subject to interactive control by at least SSTR-2/-5-dependent feedback and GHRP-dependent feedforward signals.

AB - Somatostatin antagonizes the stimulatory actions of GHRH and GH-releasing peptides (GHRPs). However, precisely how the inhibitory susceptibilities of the two secretagogues differ is not clear. One interpretative difficulty is that native somatostatin activates six different receptor subtypes. The present study adopts the complementary strategy of enforcing feedback inhibition via the preferential somatostatin receptor subtype 2 and 5 (SSTR-2/-5) agonist, octreotide. We postulated that putative SSTR-2/-5 agonism would unmask secretagogue-selective interactions in the control of GH secretory burst mass, frequency, and/or regularity. To this end, 10 healthy men each underwent eight randomly ordered, separate-day, fast ing morning infusion sessions. Interventions comprised sc administration of octreotide (1 μg/kg), followed by bolus iv injection of saline, GHRH (1 μg/kg), GHRP-2 (1 μg/kg), or both peptides. Compared with placebo, the SSTR-2/-5 agonist reduced fasting GH concentrations from 0.27 ± 0.07 to 0.12 ± 0.02 μg/liter (P = 0.020), GH secretory burst mass from 2.7 ± 0.65 to 0.55 ± 0.11 μg/liter (P = 0.013), and basal GH secretion from 0.24 ± 0.043 to 0.11 ± 0.015 μg/liter·100 min (P = 0.0063). The foregoing outcomes were selective, because octreotide did not alter GH secretory burst frequency (3.1 ± 0.5 vs. 3.3 ± 0.21 events/3 h) or the regularity of the GH release process (approximate entropy, 0.58 ± 0.048 vs. 0.68 ± 0.064). In the GHRP-2-stimulated setting, presumptive SSTR-2/-5 agonism suppressed all three GH secretory burst masses, from 28 ± 3.2 to 18 ± 2.0 (P = 0.045); GH pulse frequency, from 3.3 ± 0.30 to 2.0 ± 0.18 (P = 0.0025); and the irregularity (approximate entropy) of GH release, from 0.648 ± 0.049 to 0.433 ± 0.047 (P < 0.01). In contrast, in the GHRH and combined GHRH/GHRP-2-stimulated contexts, octreotide decreased only GH secretory burst mass (P = 0.047). In summary, the present data indicate that GH secretory burst mass, frequency, and orderliness are subject to interactive control by at least SSTR-2/-5-dependent feedback and GHRP-dependent feedforward signals.

UR - http://www.scopus.com/inward/record.url?scp=4544388635&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4544388635&partnerID=8YFLogxK

U2 - 10.1210/jc.2004-0205

DO - 10.1210/jc.2004-0205

M3 - Article

C2 - 15356066

AN - SCOPUS:4544388635

VL - 89

SP - 4581

EP - 4587

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 9

ER -